ABSTRACT: Background. The purpose of this study was to evaluate long-term outcomes after induction chemotherapy followed by "riskbased'' local therapy for locally-advanced squamous cell carcinoma of the head and neck (SCCHN). Methods. Forty-seven patients (stage IV; N2b) were enrolled in a phase II trial. Baseline and 24-month functional measures included modified barium swallow (MBS) studies, oropharyngeal swallow efficiency (OPSE), and the MD Anderson Dysphagia Inventory (MDADI). Functional status was assessed at 5 years. Results. Five-year overall survival (OS) was 89% (95% confidence interval [CI], 81% to 99%). A nonsignificant 13% average reduction in swallowing efficiency (OPSE) was observed at 24 months relative to baseline (p ¼ .191). MDADI scores approximated baseline at 24 months. Among 42 long-term survivors (median, 5.9 years), 3 patients (7.1%) had chronic dysphagia. The rate of final gastrostomy dependence was 4.8% (2 of 42). Conclusion. Sequential chemoradiotherapy achieved favorable outcomes among patients with locally advanced SCCHN, mainly of oropharyngeal origin. MBS and MDADI scores found modest swallowing deterioration at 2 years, and chronic aspiration was uncommon in long-term survivors.
INTRODUCTION
A majority of patients with squamous cell carcinomas of the head and neck (SCCHN) have stage III to IV disease at diagnosis. 1 Among patients who are candidates for nonsurgical therapy, concomitant chemoradiotherapy is a standard of care with goals of locoregional tumor control and functional organ preservation. However, this strategy is often associated with substantial toxicity and adverse functional effects. Severe (grade 3-4) late laryngopharyngeal toxicity was reported in 43% of survivors who had adequate baseline functioning in a pooled analysis of 3 Radiation Therapy Oncology Group trials of concomitant chemoradiotherapy. 2 Dysphagia is a consequence of severe laryngopharyngeal toxicity and is among the most commonly cited functional impairments after chemoradiotherapy 3, 4 with an estimated prevalence of 43% to 64%, 5, 6 and published rates of chronic gastrostomy dependence ranging from 4% to 26% dependent upon site and tumor stage. [7] [8] [9] Thus, long-term swallowing outcomes are a key metric of functional success after combined therapy. Although still investigational, sequential treatment with induction chemotherapy followed by radiotherapy for SCCHN has been shown to decrease the risk of distant metastases as a first site of tumor recurrence 10 and may lead to favorable functional outcomes. 11 In a phase II study previously reported, we treated patients with locally advanced nodal disease with induction chemotherapy consisting of weekly paclitaxel, carboplatin, and cetuximab (PCC) followed by "risk-based'' definitive treatment with radiotherapy as a single modality, concomitant chemoradiotherapy, or surgical resection based on the site and stage of disease at diagnosis. Our hypothesis when we designed this study was that induction PCC followed by risk-based local therapy would achieve durable locoregional and distant disease control at 5-years with acceptable long-term functional outcomes. The early published results of this trial demonstrated a high overall response rate of 96% after 6 weekly cycles of PCC, and promising 3-year rates of progression-free and overall survival (OS; 87% and 91%, respectively). 12 The purpose of this current study was to evaluate long-term functional and survival outcomes of this trial. 
PATIENTS AND METHODS

Eligibility and trial design
Treatment protocol
Induction chemotherapy consisted of 6 weekly cycles of PCC (paclitaxel 135 mg/m 2 , carboplatin area under the curve 2, and cetuximab 400 mg/m 2 in week 1 and then 250 mg/m 2 ). The plan for local therapy was determined with respect to disease site and stage at diagnosis and included single modality radiation for primary T1 to T2 tumors, concurrent chemoradiation for T3 to T4 tumors, or surgery for primary tumors of the oral cavity. The protocol permitted adjustment of local treatment assignments in accordance with the treating physicians' judgment, but the response to induction PCC did not dictate the local treatment assignment. Details of the induction PCC regimen, radiotherapy delivery, and concurrent therapy along with the CONSORT diagram ( Figure 1 ) have been published previously. 12 Patients were referred to speech pathology before definitive treatment for proactive swallowing therapy that included provision of swallowing exercises for patients to complete during radiotherapy. Patients were also referred for nutritional assessment by a registered dietitian before radiotherapy. Prophylactic feeding tubes were not placed unless nutritional compromise and/or dysphagia were identified in baseline assessments. A total of 33 patients (70%) received feeding tube placement. Of these, 26 patients required tube placement during radiotherapy.
Prospective functional assessment
Baseline and long-term (24 months) functional assessments were planned for all patients and included modified barium swallow (MBS) studies, the MD Anderson Dysphagia Inventory (MDADI), and the Performance Status Scale-Head and Neck (PSS-HN). The results of interim functional assessments at 6 months and 12 months posttreatment intervals have been published previously. 12 
Modified barium swallow Studies
MBS studies were conducted in standard format. 13 Video recordings of MBS studies were analyzed by blinded raters who met previously published reliability standards using 2 validated measures: Oropharyngeal Swallow Efficiency (OPSE) and the Penetration-Aspiration Scale (PAS). OPSE provides a continuous score (0 to 1) as the ratio of the percent swallowed into the esophagus (100-[% residue þ % aspiration]) divided by oropharyngeal transit time. Thus, a higher OPSE score indicates a safer and more efficient oropharyngeal swallow. 14 OPSE scores were calculated independently for each bolus type (10-mL Varibar thin liquid, pudding, cracker), and averaged across consistencies to provide a global score of swallowing efficiency at baseline and 24-month assessments. Aspiration was rated according to the PAS on 10-mL volumes of Varibar thin liquid barium (PAS range, 0 ¼ normal, 8 ¼ silent aspiration; PAS 6 coded as aspiration). 15 
Questionnaires
Two questionnaires were administered at baseline and 24 months at the time of MBS studies: (1) the MDADI, and (2) the PSS-HN. The MDADI is a validated 20-item measure of swallowing-related quality of life. MDADI global, composite, and subscale (emotional, physical, functional) scores were calculated (range, 20-100); higher scores indicate superior perception of swallowing function. The composite MDADI score was chosen as the primary summary score of swallowing-related quality of life because it reflects overall performance on 19 MDADI items. 16 The PSS-HN is a 3-item validated clinician-rated measure of disease-specific performance status based on semistructured interview. Diet levels were rated according to the PSS-HN Normalcy of Diet subscale, in which 0 indicates "non-oral nutrition'' and 100 represents "full oral nutrition without restrictions.'' Speech intelligibility was measured using the PSS-HN Understandability of Speech subscale, in which 0 indicates "never understandable'' speech and 100 represents "always understandable'' speech. Eating practices were rated according to the PSS-HN Public Eating subscale in which 0 indicates "always eats alone'' and 100 means "no restriction of food, place, or companion.'' 17 The MDADI was completed by written questionnaire at the time of MBS studies, and the PSS-HN per interview by the speech pathologist conducting the MBS study. Patients who did not return for MBS studies at 24 months were mailed both questionnaires (MDADI and PSS-HN). Mailed PSS-HN scores (n ¼ 6) 
Final functional outcomes
Final functional outcomes were ascertained from the medical record of long-term disease-free survivors. Final diet level, gastrostomy dependence, tracheostomy dependence, and laryngectomy status were recorded a minimum of 5 years after enrollment. Medical records were also reviewed to identify cases of pneumonia per radiographic infiltrates and stricture per endoscopic examination 1 year or more after treatment. A composite endpoint of chronic dysphagia was defined by chronic (1 year) aspiration or stricture per MBS, and/or permanent gastrostomy dependence. Osteoradionecrosis was graded per dental oncology records and radiographic imaging as: grade 1, minimal bone exposure with conservative management only; grade 2, minor debridement received; grade 3, hyperbaric oxygen needed; or grade 4, major surgery required. 18 
Statistical methods
Descriptive statistics were calculated to describe the sample characteristics, toxicity, and functional outcomes. Survival distributions were estimated using the Kaplan-Meier method. Statistical differences between paired data were analyzed using the nonparametric signrank test. Statistical significance was considered a-level 0.05. Statistical analyses were performed using the STATA data analysis software, version 10.0 (StataCorp LP, College Station, TX).
RESULTS
Sample characteristics
Forty-seven patients with previously untreated stage IV SCCHN (nodal classification N2b) were enrolled. The median age was 53 years; 33 patients were men. Most had oropharyngeal tumors (41 of 47; 87.2%), and 63.8% (30 of 47) had T1 or T2 primary tumors. Local therapy after induction PCC included single modality radiation (23 of 47; 48.9%), concurrent chemoradiation (23 of 47; 48.9%), or surgery with adjuvant radiotherapy (1 of 47; 2.1%). Table 1 describes patient and treatment characteristics.
Survival outcomes
The 5-year OS rate was 89% (95% confidence interval [CI], 81% to 99%), with median follow-up of 5.9 years. No patient developed new locoregional recurrence or distant metastasis since the initial report of 3-year outcomes. 12 One patient died of disease 3.9 years after enrollment and 1 patient developed a second primary spindle cell sarcoma of the scalp 5.5 years after enrollment. Figure 2 shows OS.
Longitudinal swallowing data (baseline to 24 months)
Swallowing data prospectively collected at baseline and 2 years are summarized in Table 2 
Final functional outcomes and late toxicity
Final functional outcomes are summarized in Table 3 . Functional outcomes were evaluable in 42 long-term survivors (89.4%) at a median follow-up time of 5.9 years. Overall, 3 (7.1%) long-term survivors (2 hypopharynx/ supraglottic, 1 tonsil) had chronic dysphagia defined by either chronic aspiration per MBS and/or permanent gastrostomy dependence, 2 of whom had baseline dysphagia per MBS studies. Among chronic dysphagia cases, 2 patients (2 of 42; 4.8%) experienced recurrent episodes of pneumonia in long-term follow-up (>12 months posttreatment); 1 of whom had significant baseline tumor-related dysphagia and the other developed progressive pharyngeal dysphagia within the first year of treatment. The rate of final gastrostomy dependence was 4.8% (2 of 42) and 92.9% (39 of 42) tolerated a soft or regular oral diet.
One patient with a base of tongue primary tumor required tracheostomy for stridor 19 months after chemoradiation; this patient was subsequently found to have laryngeal carcinoma in situ and underwent total laryngectomy 2 months later. No patient required permanent tracheostomy. No patient required total laryngectomy for swallowing dysfunction, and none had chronic stricture. Two patients (4.2%) developed early posttreatment esophageal stricture, and both were managed successfully with dilation within the first year of treatment. No cases of late-onset dysphagia or stricture were observed at last follow-up.
Notably, acute grade 2 peripheral neuropathy affected 15% of patients with a single patient sustaining grade 3. However, only 3 long-term survivors had persistent peripheral neuropathy (grade 1 ¼ 2 patients; and grade 2 ¼ 1 patient). Performance status (Zubrod) at last follow-up was 0 in 25 patients, 1 in 13 patients, and 2 in 4 patients.
Four patients (9.5%) developed mandibular osteoradionecrosis. Two resolved after multiple sequestrectomies (grade 2), 1 resolved with hyperbaric oxygen treatment (grade 3), and 1 required mandibulectomy with free flap reconstruction (grade 4). No patients developed secondary radiation-related tumors. 
Final functional outcomes in long-term oropharyngeal cancer survivors
The majority of long-term survivors (39 of 42) had oropharyngeal primary tumors. Only 1 (2.6%) long-term oropharyngeal cancer survivor (T3N2b squamous cell carcinoma tonsil with parapharyngeal space, pharyngeal wall, and tongue base extension) had chronic dysphagia. This patient had evidence of tumor-related dysphagia and aspiration on baseline MBS that progressed on posttreatment studies.
DISCUSSION
The long-term results of this phase II trial are favorable with respect to disease control, but also demonstrate encouraging long-term functional outcomes. We have observed a 5-year OS rate of 89% after induction PCC followed by risk-based local therapy for patients with locally advanced (N classification 2b) SCCHN. Cetuximab 12 was added to a 6-week regimen of induction paclitaxel and carboplatin, 19 and treatment planning allowed for individualized local therapy based on disease site and stage at diagnosis. Early results of this trial 12 demonstrated 3-year OS of 91% and moderate acute toxicities, most commonly grade 2 or 3 rash/folliculitis after induction PCC (83% of patients) and grade 2 or 3 mucositis attributed to definitive radiation therapy (RT) or chemoradiotherapy (CRT; 92% of patients). Herein, we describe durable locoregional control at 5 years with acceptable long-term toxicity.
Very encouraging long-term functional outcomes were observed in 42 5-year survivors after induction PCC and local therapy. Prospective functional assessments found modest, nonsignificant changes in global swallowing metrics (ie, overall OPSE and composite MDADI) at 2 years, and chronic aspiration and pneumonia were rare events (<5% of patients). Together, the functional outcomes we observed compare favorably to rates of aspiration (24% to 64%) and gastrostomy dependence (4% to 26%) reported after CRT. [7] [8] [9] Statistically significant differences identified on subscales of OPSE (paste bolus) and MDADI (physical subscale) evaluations are indicative of decreased swallowing efficiency 2 years after treatment relative to baseline performance. That is, pharyngeal residue resulting from physiologic impairments led to significantly lower OPSE scores for paste swallows despite nonsignificant changes for liquid swallows and airway protection. Likewise, among the MDADI subscales, only the physical domain scores (example items, "swallowing takes great effort,'' "it takes me longer to eat because of my swallowing problem'') were significantly lower than baseline at 2 years. Near-baseline performance on other MDADI domains suggest that patients might develop coping strategies that lessen the social and functional impact of dysphagia over time, despite persistent physical differences in swallowing abilities. Jointly, long-term performance on OPSE and MDADI suggest acceptable changes in swallowing efficiency for most patients with adjustments and adaptations to "new normal'' levels of functioning. Functional outcomes are influenced by a number of patient, clinical, and treatment factors. Baseline dysfunction, laryngeal or hypopharyngeal tumors, and T4 staging have been shown to portend unfavorable functional outcomes after organ preservation. [20] [21] [22] A majority of patients in this trial (64%) had T1 to T2 disease, few (9%) had laryngeal or hypopharyngeal tumors, and only 2 (4%) had MBS-evidence of baseline aspiration, explaining in part the satisfactory long-term functional outcomes we observed. Local therapy decisions likely also contributed to better than expected long-term functioning after the induction PCC regimen. There is evidence that induction chemotherapy does not adversely impact swallowing physiology, and notably may improve important aspects of functioning including diet levels and swallowingrelated quality of life before local therapy. 11 Conversely, both clinical and population-based studies have found highest rates of dysphagia after concurrent CRT. 6, 23 The risk-based approach used to select definitive local therapy at diagnosis successfully avoided concurrent chemotherapy in almost half of patients enrolled. In addition, our institution commonly uses a split-beam intensity-modulated radiation therapy approach for oropharyngeal cancers that has been shown to achieve a lower laryngeal and esophageal inlet dose in comparison to full intensitymodulated radiation therapy fields and may be associated with low rates of aspiration observed in this trial. 24, 25 Finally, prophylactic swallowing therapy was provided as a standard of care to patients enrolled in this trial, and included provision of targeted swallowing exercises and avoidance of nothing per oral intervals during treatment. 3 It is likely that complex interactions between baseline function, tumor burden, supportive care, and the intensity of local therapy influenced our functional outcomes, and these associations require further assessment.
Favorable 3-year disease control results of this trial were maintained at 5 years, with a 5-year OS rate of 89% after induction PCC and risk-based local therapy. However, induction chemotherapy as a component of sequential treatment for selected patients with locally advanced SCCHN continues under study. Two prospective trials, 26, 27 with patients randomized to receive docetaxel, cisplatin, and infusional fluorouracil or not followed by concomitant CRT, were presented at the 2012 American Society of Oncology general meeting this year. There was no reported significant difference in tumor control or OS between the experimental and control groups. This, in part, may have been related to better than expected outcomes in the control CRT arms. Tumor testing for human papillomavirus (HPV)-positivity was not required in these studies and the influence of this factor on results is not known. The indication for use of induction chemotherapy remains a study question.
In conclusion, we observed modest changes in swallowing efficiency 2 years after treatment, and a low prevalence of chronic aspiration and gastrostomy dependence after sequential CRT for patients with locally advanced SCCHN, mainly of oropharyngeal origin. A comparative phase 2 trial is ongoing to further investigate the efficacy of PCC versus docetaxel, cisplatin, infusional fluorouracil, and cetuximab 28 followed by risk-based local therapy in patients with SCCHN of any primary site, but again with advanced cervical nodal disease. HPV status is a stratification factor and affects planning for definitive RT. Patients who are HPV positive with T1 to T3 staging receive RT as a single modality. We continue to study sequential CRT for subgroups of patients at moderate to high risk of developing distant metastases with attention to overall disease control and maintenance of function.
